Molecular signalling pathways in canine gliomas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In this study, we determined the expression of key signalling pathway proteins TP53, MDM2, P21, AKT, PTEN, RB1, P16, MTOR and MAPK in canine gliomas using western blotting. Protein expression was defined in three canine astrocytic glioma cell lines treated with CCNU, temozolamide or CPT-11 and was further evaluated in 22 spontaneous gliomas including high and low grade astrocytomas, high grade oligodendrogliomas and mixed oligoastrocytomas. Response to chemotherapeutic agents and cell survival were similar to that reported in human glioma cell lines. Alterations in expression of key human gliomagenesis pathway proteins were common in canine glioma tumour samples and segregated between oligodendroglial and astrocytic tumour types for some pathways. Both similarities and differences in protein expression were defined for canine gliomas compared to those reported in human tumour counterparts. The findings may inform more defined assessment of specific signalling pathways for targeted therapy of canine gliomas.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - 2015

Fingerprint

Glioma
Canidae
dogs
Astrocytoma
irinotecan
neoplasms
protein synthesis
cell lines
Lomustine
Tumor Suppressor Protein p53
Oligodendroglioma
Cell Line
Neoplasms
Proteins
cell viability
Western blotting
proteins
Cell Survival
Western Blotting
therapeutics

Keywords

  • Astrocytoma
  • Brain tumour
  • Canine glioma cell lines
  • Oligodendroglioma
  • Signalling pathways
  • Western blotting

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{6518692b05a94582858048db06eb1632,
title = "Molecular signalling pathways in canine gliomas",
abstract = "In this study, we determined the expression of key signalling pathway proteins TP53, MDM2, P21, AKT, PTEN, RB1, P16, MTOR and MAPK in canine gliomas using western blotting. Protein expression was defined in three canine astrocytic glioma cell lines treated with CCNU, temozolamide or CPT-11 and was further evaluated in 22 spontaneous gliomas including high and low grade astrocytomas, high grade oligodendrogliomas and mixed oligoastrocytomas. Response to chemotherapeutic agents and cell survival were similar to that reported in human glioma cell lines. Alterations in expression of key human gliomagenesis pathway proteins were common in canine glioma tumour samples and segregated between oligodendroglial and astrocytic tumour types for some pathways. Both similarities and differences in protein expression were defined for canine gliomas compared to those reported in human tumour counterparts. The findings may inform more defined assessment of specific signalling pathways for targeted therapy of canine gliomas.",
keywords = "Astrocytoma, Brain tumour, Canine glioma cell lines, Oligodendroglioma, Signalling pathways, Western blotting",
author = "Boudreau, {C. E.} and Daniel York and Robert Higgins and Lecouteur, {Richard A} and Dickinson, {Peter J}",
year = "2015",
doi = "10.1111/vco.12147",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Molecular signalling pathways in canine gliomas

AU - Boudreau, C. E.

AU - York, Daniel

AU - Higgins, Robert

AU - Lecouteur, Richard A

AU - Dickinson, Peter J

PY - 2015

Y1 - 2015

N2 - In this study, we determined the expression of key signalling pathway proteins TP53, MDM2, P21, AKT, PTEN, RB1, P16, MTOR and MAPK in canine gliomas using western blotting. Protein expression was defined in three canine astrocytic glioma cell lines treated with CCNU, temozolamide or CPT-11 and was further evaluated in 22 spontaneous gliomas including high and low grade astrocytomas, high grade oligodendrogliomas and mixed oligoastrocytomas. Response to chemotherapeutic agents and cell survival were similar to that reported in human glioma cell lines. Alterations in expression of key human gliomagenesis pathway proteins were common in canine glioma tumour samples and segregated between oligodendroglial and astrocytic tumour types for some pathways. Both similarities and differences in protein expression were defined for canine gliomas compared to those reported in human tumour counterparts. The findings may inform more defined assessment of specific signalling pathways for targeted therapy of canine gliomas.

AB - In this study, we determined the expression of key signalling pathway proteins TP53, MDM2, P21, AKT, PTEN, RB1, P16, MTOR and MAPK in canine gliomas using western blotting. Protein expression was defined in three canine astrocytic glioma cell lines treated with CCNU, temozolamide or CPT-11 and was further evaluated in 22 spontaneous gliomas including high and low grade astrocytomas, high grade oligodendrogliomas and mixed oligoastrocytomas. Response to chemotherapeutic agents and cell survival were similar to that reported in human glioma cell lines. Alterations in expression of key human gliomagenesis pathway proteins were common in canine glioma tumour samples and segregated between oligodendroglial and astrocytic tumour types for some pathways. Both similarities and differences in protein expression were defined for canine gliomas compared to those reported in human tumour counterparts. The findings may inform more defined assessment of specific signalling pathways for targeted therapy of canine gliomas.

KW - Astrocytoma

KW - Brain tumour

KW - Canine glioma cell lines

KW - Oligodendroglioma

KW - Signalling pathways

KW - Western blotting

UR - http://www.scopus.com/inward/record.url?scp=84926442997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926442997&partnerID=8YFLogxK

U2 - 10.1111/vco.12147

DO - 10.1111/vco.12147

M3 - Article

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -